Zepbound Returns to CVS Caremark as Massachusetts Faces Equity Pushback on GLP-1 Cuts
Thursday, October 1, 2026 · 10 min
Zepbound is back on CVS Caremark's standard commercial formulary starting October 1, but employers still decide, while Massachusetts critics press the state to undo its GLP-1 weight-loss coverage cuts. Plus a JAMA Health Forum Medicaid study on prior authorization, Lilly-sponsored ACHIEVE-4 heart-safety data for Foundayo in The Lancet, and California's new CalRx GLP-1 law.
Listen
Show notes
Zepbound is back on CVS Caremark's standard commercial formulary starting October 1, but employers still decide, while Massachusetts critics press the state to undo its GLP-1 weight-loss coverage cuts. Plus a JAMA Health Forum Medicaid study on prior authorization, Lilly-sponsored ACHIEVE-4 heart-safety data for Foundayo in The Lancet, and California's new CalRx GLP-1 law.
In this episode
- CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment — Skinnyvip
CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment # CVS Caremark Adds Zepbound Back October 1, 2026: What to Ask HR Before Open Enrollment Dr. SkinnyVIP September 15, 2026 ~9 min read Formulary details current as of September 15, 2026 This guide summarizes CVS Caremark’s May 28, 2026 announcement and standard commercial formulary template as of the…
- Critics say GLP-1 coverage shift raises equity issues — The Boston Globe
# Critics say GLP-1 coverage shift raises equity issues Author: Alison Kuznitz Published: 2026-09-30T21:56:03.616000+00:00 Source: bostonglobe.com (bostonglobe.com) Language: en ## Story Critics say GLP-1 coverage shift raises equity issues # Critics say GLP-1 coverage shift raises equity issues A woman holds a Wegovy injector pen in her Wenatchee, Wash., home, on June 3, 2024. M. SCOTT…
- Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version — Drugtopics
# Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version Published: 2026-09-30T14:00:00+00:00 Source: drugtopics.com (drugtopics.com) Language: en ## Story --- ## title: "Medicaid Coverage of Obesity GLP-1s May Shift From Diabetes Version" description: "Medicaid coverage of obesity-labeled GLP-1 receptor agonists may substitute for, rather than simply add to, diabetes-labeled…
- Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study — EurekAlert!
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study # Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study By PR Newswire | September 30, 2026,…
- Newsom signs law allowing California-made GLP-1 drugs — Redding
Newsom signs law allowing California-made GLP-1 drugs # California’s GLP-1 law could expand access to obesity treatment Ernesto Centeno Araujo USA TODAY NETWORK Sept. 29, 2026, 4:42 p.m. PT Gov. Gavin Newsom recently signed a law that would allow California to make and distribute a generic version of a popular class of weight-loss drugs through the state's CalRx program. California…